Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3851 - IMpassion131: Phase III Study Comparing 1L Atezolizumab With Paclitaxel vs Placebo With Paclitaxel in Treatment-Naive Patients with Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer (mTNBC)

Date

11 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Immunotherapy;  Breast Cancer

Presenters

David Miles

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

D. Miles1, F. Andre2, J. Gligorov3, S. Verma4, B. Xu5, D. Cameron6, C.H. Barrios7, A. Schneeweiss8, V. Easton9, I. Dolado10, J. O'Shaughnessy11

Author affiliations

  • 1 Medical Oncoloy, Mount Vernon Cancer Centre, HA6 2RN - Northwood/GB
  • 2 Medical Oncoloy, Gustave Roussy, Villejuif/FR
  • 3 Medical Oncoloy, Institut Universitaire de Cancérologie, IUC-UPMC, Sorbonne Univeristy, Paris/FR
  • 4 Oncology, Cumming School of Medicine, University of Calgary Alberta Health Services, Calgary/CA
  • 5 Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 - Beijing/CN
  • 6 Mrc Institute Of Genetics & Molecular Medicine, Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh/GB
  • 7 Department Of Medicine, PUCRS School of Medicine, Porto Alegre/BR
  • 8 Division Gynecologic Oncology, National Center for Tumor Diseases (NTC) University Hospital, Heidelberg/DE
  • 9 Global Pdma (biometrics), F. Hoffmann-La Roche AG, Basel/CH
  • 10 Global Pdma, F. Hoffmann-La Roche AG, Basel/CH
  • 11 Texas Oncology, Baylor University Medical Center, US Oncology, Dallas/US
More

Resources

Abstract 3851

Background

Chemotherapy (including paclitaxel [pac]) remains the main 1L treatment for metastatic TNBC but brings limited clinical benefit, highlighting the need for new treatments. Atezolizumab (atezo) blocks the interaction of PD-L1 with receptors PD-1 and B7.1, thus restoring anti-tumor immunity. TNBC is a rational target for atezo due to high PD-L1 expression, elevated T-cell tumor infiltration and high mutational burden. Atezo alone and in combination with nab-pac was well tolerated, with no exacerbation of chemo-associated adverse events, and demonstrated promising clinical activity in mTNBC. Atezo + nab-pac is being further investigated as 1L TNBC treatment in IMpassion130. IMpassion131, a global, multi-center, randomized, double-blind, placebo (pbo)-controlled study, is comparing the efficacy and safety of 1L atezo + pac vs pbo + pac in patients (pts) with untreated, inoperable, locally advanced or metastatic TNBC.

Trial design

Eligible pts are those with inoperable, locally advanced or metastatic TNBC, histologically confirmed; de novo or recurrent disease after early BC chemo treatment completed ≥ 12 mo prior; taxane monotherapy eligible; no prior chemo or targeted systemic therapy for inoperable locally advanced or metastatic disease; ECOG PS 0-1 and measurable disease by RECIST v1.1. Exclusion criteria include known symptomatic CNS disease, prior immunotherapy and history of autoimmune disease. Approximately 495 pts will be randomized 2:1 to receive atezo (840 mg) or pbo (q2w; days 1 and 15 of 28-day cycle) plus pac (90 mg/m2; days 1, 8, 15 of 28-day cycle) until disease progression. Stratification factors are PD-L1 expression on tumor-infiltrating immune cells (IC; IC0 [< 1%] vs IC1/2/3 [≥ 1%] with VENTANA SP142 IHC assay), prior taxane therapy, presence of liver metastases and geographical region. The primary endpoint is PFS measured by RECIST v1.1. Key secondary endpoints include OS, 12- and 18-month OS rates, 12-month PFS rate, ORR, DOR, and safety. Tumor biopsies will be investigated at baseline, on treatment and at progression to assess biomarkers of response and immune escape.

Clinical trial identification

NCT03125902

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.

Funding

F. Hoffmann-La Roche Ltd.

Disclosure

D. Miles: Honoraria for Advisory Boards from Roche-Genentech. F. Andre: Research grants: AstraZeneca, Novartis, PF, Lilly. J. Gligorov: Advisory boards: Eisai, GenomicHealth, Novartis, Pfizer, Roche. Granted research: Eisai, Roche. D. Cameron: Employer paid for consultancy work done with Roche. Hospital has also been reimbursed for costs incurred in doing clinical research by Roche. C.H. Barrios: Research: Pfizer, Novartis, Amgen, AstraZeneca, Boehringer Ingelheim, Roche, Lilly, Sanofi, GSK, Taiho, Mylan, Merrimack, Merck, Astellas, Bristol-Myers Squibb. Consulting: Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche-Genentech, Eisai. A. Schneeweiss: Member of Roche advisory boards. Member of IMpassion 130 steering committee. Honoraria and financial support from Roche for presentations at academic meetings. V. Easton, I. Dolado: Roche employee and stock. J. O\'Shaughnessy: Consultant to Genentech and Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.